Christian F Singer

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi Systemic HCG treatment in patients with endometriosis: a new perspective for a painful disease
    Ambros V Huber
    Division of Perinatal Medicine, Department of Ob Gyn, Medical University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 116:839-43. 2004
  2. pmc Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay
    Christian F Singer
    Department of Gynecology and Obstetrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    PLoS ONE 8:e66573. 2013
  3. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
  4. pmc Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Breast Cancer Res 14:R42. 2012
  5. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  6. doi [Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families]
    Christian F Singer
    Universitatsklinik fur Frauenheilkunde, MUW AKH Wien, Wien, Osterreich
    Wien Klin Wochenschr 124:334-9. 2012
  7. pmc Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
    Logan C Walker
    Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 12:R102. 2010
  8. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
  9. pmc Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing
    Matthias Wielscher
    Molecular Medicine, Austrian Institute of Technology, Muthgasse 11, 1190 Vienna, Austria
    BMC Clin Pathol 11:11. 2011
  10. ncbi Differential gene expression profile in breast cancer-derived stromal fibroblasts
    Christian F Singer
    Department of Ob Gyn, Division of Special Gynecology, Medical University of Vienna, Vienna, Austria
    Breast Cancer Res Treat 110:273-81. 2008

Detail Information

Publications68

  1. ncbi Systemic HCG treatment in patients with endometriosis: a new perspective for a painful disease
    Ambros V Huber
    Division of Perinatal Medicine, Department of Ob Gyn, Medical University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 116:839-43. 2004
    ....
  2. pmc Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay
    Christian F Singer
    Department of Gynecology and Obstetrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    PLoS ONE 8:e66573. 2013
    ..This is the first prospective clinical trial to demonstrate the utility of a standardized in vitro chemosensitivity assay in predicting the individual biological response to chemotherapy in breast cancer. ..
  3. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
    ..2)...
  4. pmc Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Breast Cancer Res 14:R42. 2012
    ..We present an updated analysis of breastfeeding and risk of breast cancer using a large matched sample of BRCA mutation carriers...
  5. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  6. doi [Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families]
    Christian F Singer
    Universitatsklinik fur Frauenheilkunde, MUW AKH Wien, Wien, Osterreich
    Wien Klin Wochenschr 124:334-9. 2012
    ..The guideline is aimed at facilitating and standardizing the care and early detection strategies in women with an elevated life time risk for breast and ovarian cancer...
  7. pmc Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
    Logan C Walker
    Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 12:R102. 2010
    ..In this study, we evaluated 24 SNPs tagged to 14 candidate genes derived through a novel approach that analysed gene expression differences to prioritise candidate modifier genes for association studies...
  8. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
    ..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations...
  9. pmc Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing
    Matthias Wielscher
    Molecular Medicine, Austrian Institute of Technology, Muthgasse 11, 1190 Vienna, Austria
    BMC Clin Pathol 11:11. 2011
    ..abstract:..
  10. ncbi Differential gene expression profile in breast cancer-derived stromal fibroblasts
    Christian F Singer
    Department of Ob Gyn, Division of Special Gynecology, Medical University of Vienna, Vienna, Austria
    Breast Cancer Res Treat 110:273-81. 2008
    ..While tumor-derived fibroblasts display unique phenotypic properties, it is unclear whether they also represent are a specific subpopulation...
  11. ncbi Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism
    Christian F Singer
    Division of Special Gynecology, University of Vienna Medical Center, Waehringer Guertel 18 20, 1090, Vienna, Austria
    Endocr Relat Cancer 13:1101-7. 2006
    ..Our results indicate a net increase in intratumoral active estrogen levels through increased stromal aromatization, while physiological local inactivation by sulfotransferase activity remains essentially unchanged...
  12. ncbi Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity
    C F Singer
    Division of Special Gynecology and Ludwig Boltzmann Institute of Clinical Experimental Oncology, University of Vienna Medical Center, Vienna, Austria
    Int J Gynecol Cancer 16:556-9. 2006
    ..We suggest that the expression of IL-1alpha in poorly differentiated, ERalpha-negative tumors contributes to their malignant phenotype...
  13. ncbi Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition
    Christian F Singer
    Division of Senology, University of Vienna, Vienna, Austria
    Oncol Rep 15:353-9. 2006
    ..We further suggest that pCrkL might serve as a potential surrogate parameter for the efficacy of therapeutic TK inhibition...
  14. ncbi Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors
    Christian F Singer
    Department of Senology and Ludwig Boltzmann Institute of Clinical Experimental Oncology, University of Vienna, Austria
    Endocr Relat Cancer 11:861-9. 2004
    ..Taken together, we have found a specific pattern of kinase co-expression and have identified several potential targets for a tumor-specific multimodal TK inhibition...
  15. doi [Principles and method of action of targeted therapies]
    Christian F Singer
    Arbeitsgruppe Senologie der Klinischen Abteilung für Allgemeine Gynäkologie und Gynäkologische Onkologie, Universitatsklinik fur Frauenheilkunde, Medizinische Universität Wien, Osterreich
    Wien Med Wochenschr 160:501-5. 2010
    ..Both strategies ultimately lead to an inhibition of the signal transduction cascade and thereby block increased cell proliferation, metastasis, or the production of new blood or lymph vessels...
  16. doi Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells
    Christian F Singer
    Department of Obstetrics, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Endocr Relat Cancer 16:73-83. 2009
    ..We hypothesize that receptor phosphorylation is caused by growth factor stimulation in response to intraoperative tissue damage, and perioperative inhibition of specific cytokines could become a promising therapeutic strategy...
  17. doi HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer
    Christian F Singer
    Division of Special Gynaecology, Vienna Medical University, Vienna, Austria
    J Cancer Res Clin Oncol 135:807-13. 2009
    ..It has been suggested that that in HER2 over-expressing tumors, cross-talk via activated HER2 receptors is a key mechanisms by which tumors become tamoxifen-resistant...
  18. doi Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies
    Christian F Singer
    Division of Special Gynecology, Medical University of Vienna and Ludwig Boltzmann Institute of Clinical and Experimental Oncology, Vienna, Austria
    Biochim Biophys Acta 1786:105-13. 2008
    ....
  19. ncbi Presence of intratumoral stem cells in breast cancer patients with or without BRCA germline mutations
    C F Singer
    Division of Special Gynaecology, Vienna Medical University, Vienna, Austria
    Curr Cancer Drug Targets 12:44-50. 2012
    ..The underlying causes of the characteristic phenotypic behavior are not completely understood, but mammary stem cells appear to have a key role in this process...
  20. ncbi Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer
    Christian F Singer
    Division of Special Gynaecology, Vienna Medical University, Vienna, Austria
    Clin Exp Metastasis 23:33-9. 2006
    ....
  21. ncbi Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype
    Christian F Singer
    Division of Special Gynecology, University of Vienna Medical Center, 1090 Vienna, Austria
    Clin Cancer Res 9:4877-83. 2003
    ..However, little is known about its expression in breast cancer and its correlation with prognostic parameters such as receptor status and grading...
  22. ncbi Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
    Gernot Hudelist
    Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Vienna, Austria
    Eur J Cancer 42:186-92. 2006
    ..We therefore conclude that the measurement of systemic sEGFR levels in addition to ECD serum concentrations do not allow the prediction of clinical course of trastuzumab-treated patients more accurately...
  23. ncbi Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
    Gernot Hudelist
    Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Vienna, Austria
    Int J Cancer 118:1126-34. 2006
    ..We hypothesize that the activation state of both Her-2/neu and EGFR are key determinants for trastuzumab efficacy...
  24. ncbi Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer
    Wolfgang J Kostler
    Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, 18 20 Waehringer Guertel, 1090, Vienna, Austria
    J Cancer Res Clin Oncol 132:9-18. 2006
    ..The present analysis was performed to evaluate the clinical relevance of IGF-1R expression within the context of trastuzumab-based therapy...
  25. doi Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis?
    Gernot Hudelist
    Division of Special Gynecology, Department of Ob Gyn, Vienna Medical University, Waehringer Guertel 18 20, 1090, Vienna, Austria
    J Cancer Res Clin Oncol 135:191-5. 2009
    ..Whereas some reports suggest a protective effect of b-HCG on breast epithelium, vitro studies implicate a role of b-HCG/LH-R in the development and growth of breast tumors...
  26. doi Administration of betaHCG leads to dose-dependent changes of gene expression signature of endometriotic stromal cells
    Gernot Hudelist
    Division of Special Gynecology, Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Reprod Biomed Online 20:699-706. 2010
    ....
  27. doi The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells
    Caroline Brünner-Kubath
    Signaling Networks Program, Division of Oncology, Department of Medicine I, Medical University Vienna, Waehringer Guertel 18 20, 1090, Vienna, Austria
    Breast Cancer Res Treat 129:387-400. 2011
    ....
  28. ncbi The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
    Wolfgang J Kostler
    Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, 18 20 Waehringer Guertel, 1090, Vienna, Austria
    J Cancer Res Clin Oncol 131:420-8. 2005
    ..The present study was performed to corroborate previous in vitro findings from our laboratory showing that trastuzumab induces growth arrest and apoptosis in a p53-independent manner...
  29. ncbi Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
    Günther G Steger
    Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:2012-8. 2007
    ..This phase III trial evaluated whether doubling the number of cycles of neoadjuvant treatment increased the pCR rate...
  30. ncbi Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer
    Anneliese Fink-Retter
    Division of Special Gynecology, Medical University of Vienna, 1090 Vienna, Austria
    Oncol Rep 18:299-304. 2007
    ..Our findings of decreased intratumoral EGFR expression and the absence of activated EGFR suggests that, in contrast to HER2, EGFR inhibition might not be an ideal target for antibody therapy...
  31. doi Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer
    Zsuzsanna Bago-Horvath
    Departments of Pathology, Surgery, Special Gynecology, and Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 17:7828-34. 2011
    ..To assess the predictive value of Ki67 expression in postmenopausal hormone receptor-positive early-breast cancer patients, who were either treated with adjuvant tamoxifen (TAM) alone or with TAM followed by anastrozole (ANA)...
  32. doi Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group
    Peter C Dubsky
    Medical University of Vienna, Austria
    J Clin Oncol 30:722-8. 2012
    ....
  33. ncbi EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR
    Daphne Gschwantler-Kaulich
    Division of Special Gynecology, Department of Ob Gyn, Vienna Medical University, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Oncol Rep 14:305-11. 2005
    ..Taken together, we have demonstrated the activation pattern of EGFR and Her-2/neu in Her-2/neu overexpressing breast cancer. We suggest that EGFR inhibition might enhance the efficacy of trastuzumab by preventing cross-phosphorylation...
  34. ncbi Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience
    Wolfgang J Kostler
    Clinical Division of Oncology, Department of Medicine I, University Hospital of Vienna, Vienna, Austria
    Anticancer Drugs 16:185-90. 2005
    ..This needs to be confirmed in prospective randomized trials...
  35. pmc Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients
    Eva Obermayr
    Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    BMC Cancer 10:666. 2010
    ..Therefore, we aimed to identify new gene markers for the PCR-based detection of CTC in female cancer patients...
  36. ncbi Gene expression profiling of cervical tissue during physiological cervical effacement
    Ambros Huber
    Division of Obstetrics, Department of Ob Gyn, Medical University of Vienna, Vienna, Austria
    Obstet Gynecol 105:91-8. 2005
    ..The purpose of this study was to gain insight into the complex transformational changes in gene expression that lead to cervical effacement...
  37. ncbi Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue
    Gernot Hudelist
    Department of Obstetrics and Gynecology, Division of Special Gynecology, University of Vienna Medical Center, Vienna, Austria
    Breast Cancer Res Treat 86:281-91. 2004
    ..We hypothesize that the use of protein arrays will not only increase our understanding of the molecular events, but could prove useful in evaluating prognosis and in determining optimal antineoplastic therapy...
  38. ncbi Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator
    Gernot Hudelist
    Department of Senology and Ludwig Boltzmann Institute of Clinical Experimental Oncology, University of Vienna, Vienna, Austria
    Breast Cancer Res Treat 78:193-204. 2003
    ....
  39. doi Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases
    Daphne Gschwantler-Kaulich
    Division of Special Gynaecology, University of Vienna Medical Center, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Tumour Biol 32:501-8. 2011
    ....
  40. doi Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals
    Eva Katrin Bentz
    Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Vienna, Austria
    Fertil Steril 94:2688-96. 2010
    ..To evaluate gene expression signatures of breast tissue in female-to-male (FtM) transsexuals under cross-sex hormone therapy (HT)...
  41. ncbi Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium
    Gernot Hudelist
    Division of Special Gynecology, Department of Obstetrics Gynecology, Vienna Medical University, Vienna, Austria
    Proteomics 6:1989-2002. 2006
    ..This strategy leads to a better understanding of oncogenesis at an operational level and helps to characterize the malignant phenotype of individual tumors, and thereby to identify novel targets for antineoplastic therapy...
  42. ncbi Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer
    Wolfgang J Kostler
    Clinical Division of Oncology, Department of Medicine I, University Hospital of Vienna, Vienna, Austria
    Anticancer Res 24:1127-30. 2004
    ....
  43. pmc Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients
    Dan Tong
    Department of Obstetrics and Gynaecology, Medical University of Vienna, EBO 5Q, AKH, Wahringer Gurtel 18 20, Vienna 1090, Austria
    BMC Cancer 10:682. 2010
    ..We want to evaluate the prognostic impact of the expression of these genes on breast cancer...
  44. ncbi Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size
    Christian F Singer
    Division of Special Gynecology, Department of Obstetrics and Gynecology, Ludwig Boltzmann Institute of Clinical Experimental Oncology, Center of Clinical and Experimental Oncology, Vienna, Austria
    Clin Cancer Res 10:4003-9. 2004
    ..This study evaluated IGF-I and IGF-II serum levels in healthy women and in patients with benign and malignant breast lesions and correlated them with tumor size...
  45. ncbi Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis
    Gernot Hudelist
    Special Gynecology, Medical University of Vienna, Vienna, Austria
    Fertil Steril 84:1249-56. 2005
    ....
  46. doi Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial
    Georg Pfeiler
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    J Clin Oncol 29:2653-9. 2011
    ....
  47. ncbi Effect of highly purified human chorionic gonadotropin preparations on the gene expression signature of stromal cells derived from endometriotic lesions: potential mechanisms for the therapeutic effect of human chorionic gonadotropin in vivo
    Ambros Huber
    Division of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria
    Fertil Steril 88:1232-9. 2007
    ..To investigate alterations in the overall gene expression profile of endometriosis-derived stroma with increasing concentrations of hCG by using the Affymetrix GeneChip U133 Set...
  48. ncbi Use of high-throughput arrays for profiling differentially expressed proteins in normal and malignant tissues
    Gernot Hudelist
    Division of Special Gynecology, Department of Obstetrics and Gynecology, University of Vienna Medical Center, Vienna, Austria
    Anticancer Drugs 16:683-9. 2005
    ..We also present a number of studies that have already shown the clinical utility of high-throughput protein assays, and which exemplify potential applications for this young and extremely promising technology...
  49. doi beta-HCG/LH receptor (beta-HCG/LH-R) expression in eutopic endometrium and endometriotic implants: evidence for beta-HCG sensitivity of endometriosis
    Gernot Hudelist
    Division of Special Gynaecology, Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna, Austria
    Reprod Sci 15:543-51. 2008
    ..The aim of the present study was to investigate the expression of HCG/LH-R in endometriosis to elucidate a possible impact of LH and HCG on this disease...
  50. doi Impact of AdipoR1 expression on breast cancer development
    Georg Pfeiler
    Department of Obstetrics and Gynecology, Division of Special Gynecology, University of Vienna, Vienna, Austria
    Gynecol Oncol 117:134-8. 2010
    ..While AdipoR1 is known to be expressed in invasive tumors, its role in DCIS remains elusive. We therefore investigated AdipoR1 expression in both invasive and preinvasive breast cancer...
  51. doi Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations
    Anne Catharina Dressler
    Clinical Division of Gynaecology and Gynaecological Oncology, Department of Obstretrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    J Cancer Res Clin Oncol 139:1349-55. 2013
    ..We have therefore investigated the expression of both tuberin and p27 in normal breast tissue, and in malignant epithelium from women with and without a BRCA mutation...
  52. doi Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells
    Thomas W Grunt
    Signaling Networks Program, Department of Medicine I, Medical University Vienna, Vienna, Austria
    Biochem Biophys Res Commun 385:454-9. 2009
    ..Taken together, interference with FASN and ErbB abrogates their oncogenicity and should be exploited for ovarian cancer treatment...
  53. ncbi MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions
    Christian F Singer
    Division of Senology, Vienna University Medical Center, and Ludwig Boltzmann Institute for Clinical Experimental Oncology, Austria
    Breast Cancer Res Treat 72:69-77. 2002
    ..In contrast, MMP-9 expression tumor-derived fibroblasts requires direct contact with malignant tumor epithelium...
  54. ncbi Extracellular matrix proteins influence phenotype and cytokine expression in human breast cancer cell lines
    Kora Hirtenlehne
    Department of Obstetrics and Gynecology, Division of Special Gynecology, University of Vienna Medical Center and Ludwig Boltzmann Institute of Clinical Experimental Oncology, Vienna, Austria
    Eur Cytokine Netw 13:234-40. 2002
    ..This study also shows that the surface on which cells are cultured greatly influences cell kinetics and the cytokine expression pattern...
  55. ncbi Pharmacological modulation of IGF serum concentrations as a therapeutic approach to control the growth of malignant breast tumors
    Christian F Singer
    Division of Special Gynecology, University of Vienna Medical Center, and Ludwig Boltzmann Institute for Clinical Experimental Oncology, Vienna, Austria
    Drugs Today (Barc) 39:115-25. 2003
    ....
  56. ncbi Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial
    Ernst Kubista
    Division of Special Gynecology, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:4185-90. 2007
    ..5 mg tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma carcinoma tissue)...
  57. ncbi Pharmacological modulation of local feedback mechanisms as a therapeutic approach in breast cancer treatment
    Christian F Singer
    Division of Special Gynecology, University of Vienna Medical Center and Ludwig Boltzmann Institute of Clinical and Experimental Oncology, Vienna, Austria
    Drugs Today (Barc) 39:917-26. 2003
    ....
  58. doi Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age
    Muy Kheng M Tea
    Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria
    Maturitas 75:148-51. 2013
    ..We, therefore, hypothesized that FMR1 genotypes may be associated with menarcheal and menopausal ages of BRCA mutation carriers...
  59. ncbi Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade
    Gernot Hudelist
    Department of Gynecology and Obstetrics, Division of Special Gynecology, University of Vienna Medical Center, Vienna, Austria
    Gynecol Oncol 92:873-80. 2004
    ..Several high-risk (HR-)HPV subtypes have been identified, which lead to CIN and subsequently to invasive carcinoma. The reason for this phenomenon is still unknown, but it seems to be related to the physical state of HPV DNA...
  60. doi Increase in ezrin expression from benign to malignant breast tumours
    Daphne Gschwantler-Kaulich
    Department of Ob Gyn, Division of General Gynecology and Gynecologial Oncology, Medical University of Vienna, Waehringer Guertel 18 20, 1090, Vienna, Austria
    Cell Oncol (Dordr) 36:485-91. 2013
    ..We have, therefore, set out to investigate ezrin protein expression in a series of primary breast lesions...
  61. pmc Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma
    Bernd Kubista
    Department of Orthopedics, Medical University of Vienna, Vienna, Austria
    Int Orthop 35:401-11. 2011
    ..Our results show the utility of gene expression analysis to study osteosarcoma subtypes, and we identified several genes that may play a role as potential therapeutic targets in the future...
  62. doi Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer
    Katharina Tomek
    Signaling Networks Program, Division of Oncology, Department of Medicine I, Comprehensive Cancer Center, Medical University Vienna, Vienna A 1090, Austria
    Mol Cancer Res 9:1767-79. 2011
    ..FASN is a promising cancer target, whose inhibition not only abrogates lipogenesis, which is indispensable for cancer growth, but also downregulates oncogenic PI3K signaling...
  63. doi Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer
    Muy Kheng M Tea
    Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Electronic address
    Maturitas 77:68-72. 2014
    ..Therefore, we investigated the risks for BC and OC associated with brca2 mutations in a cohort of female mutation carriers of a genetically heterogeneous Central European population...
  64. doi A cross-sectional study of elderly Asian and European women with primary operable breast cancer aged 70 and older. Are there differences?
    Muy Kheng M Tea
    Fudan University Shanghai, Cancer Institute, Department of Breast Surgery, Shanghai, China
    Maturitas 73:251-4. 2012
    ..Additionally, BC-incidence is rising in Asia. The aim of this study was to explore clinico-pathological characteristics and differences of breast cancer in elderly Asian/Han-Chinese compared to Caucasian/Austrian women...
  65. pmc BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 sub-genotypes: explanation for the "BRCA paradox"?
    Andrea Weghofer
    The Center for Human Reproduction, New York, New York, United States of America
    PLoS ONE 7:e44753. 2012
    ....
  66. ncbi Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
    Wolfgang J Kostler
    Department of Medicine I, University Hospital of Vienna, Austria
    Clin Cancer Res 10:1618-24. 2004
    ....
  67. ncbi Recurrent malignant Triton tumour: first report on a long time survivor
    Wolfgang J Kostler
    Clinical Division of Oncology, Department of Medicine I, University Hospital of Vienna, 18 20 Waehringer Guertel, A 1090 Vienna, Austria
    Oncol Rep 10:533-5. 2003
    ..This is the first report on a long-term survivor of multiple recurrences of malignant Triton tumour...
  68. ncbi Circulating ovarian steroids and endometrial matrix metalloproteinases (MMPs)
    Patrick Henriet
    Cell Biology Unit, Christian de Duve Institute of Cellular Pathology, Universite Catholique de Louvain, Brussels, Belgium
    Ann N Y Acad Sci 955:119-38; discussion 157-8, 396-406. 2002
    ..Focal changes in type or abundance of sex steroid receptors also could be responsible for spatial variation in the expression of MMPs in the endometrium and endometriotic lesions...